Have you started noticing changes in your memory or ability to think clearly?

The Altitude-AD clinical research study is enrolling participants with Early Alzheimer's Disease.

If you or a loved one has been diagnosed with Mild Cognitive Impairment (MCI) or Mild Alzheimer’s disease, or have concerns about changes in memory or thinking, you or they may be eligible to participate in a new clinical trial to help advance the treatment of Early Alzheimer’s disease.

About the Study

Altitude-AD Study is a clinical trial for participants with Early Alzheimer’s disease. The purpose of this trial is to determine if an investigational medication (ACU-193) is safe and effective in slowing down the progression of Alzheimer’s disease.

The study medication is an investigational drug that has not been approved by the US Food and Drug Administration (FDA), or any regulatory agency, for the treatment of any condition.

To be considered for the Altitude-AD study, participants must:

Be ages 50 to 90 years old
Be diagnosed with Mild Cognitive Impairment or Mild Alzheimer’s disease, or have concerns about changes in memory or thinking abilities
Have experienced a gradual change in memory for six months or more
Have a study partner who knows the participant well and is willing to come to study visits

Other criteria apply.

About the Altitude-AD Study for Early Alzheimer’s Disease

The Altitude-AD Study is a clinical research study evaluating the safety and effectiveness of an investigational drug for people with Mild Cognitive Impairment (MCI) or Mild Alzheimer’s disease

If you're selected for the study....

Participants will also be asked to complete other study related activities, which will be shared in detail in informed consent forms prior to participants and study partners enrolling in the study.

If a participant qualifies, participation can last up to 80 weeks with up to 26 visits at our study center.

All study related care will be provided at no cost to you. Health Insurance is not required.

About the Early Stages of Alzheimer's Disease

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) includes problems with memory or thinking which are serious enough to be noticed by family or friends. Generally, these changes do not impact a person’s day-to-day functioning.

Approximately 12-18% of people over the age of 60 have Mild Cognitive Impairment (MCI), which may be an indicator of Early Alzheimer’s disease

About one-third of people living with MCI due to Alzheimer’s disease develop dementia within five years.

Risk factors for developing Alzheimer’s disease include age, family history and other medical conditions.

Source: Alzheimer’s Association

Mild Alzheimer's Disease

In the Mild Alzheimer’s disease, people may still function independently. They may be able to drive, participate in social activities with family or friends and tend to day-to-day activities, like preparing meals or completing household tasks.

Common problems people have at this stage include:

Increasing forgetfulness of recent or upcoming events.
More trouble finding the right words to use.
Difficulty remembering new information, like names of unfamiliar people, recent events, information they have read or learned watching TV.
Losing or misplacing important or valuable items.
More difficulties planning activities or following multi-step instructions.
Needing more help managing finances, like balancing the checkbook or paying bills.

Source: Alzheimer’s Association

People who qualify to participate will be randomly assigned to one of three groups and receive one of two doses of investigational medication or placebo. Study drug is administered at our office, once a month intravenously (by I.V.). Participants will also be asked to complete other study related activities, which will be shared in detail in informed consent forms prior to participants and study partners enrolling in the study.

If a participant qualifies, participation can last up to 80 weeks with up to 26 visits at our study center.